-
POZEN Reports Q4 EPS of $0.61
Wednesday, March 9, 2011 - 8:35am | 61POZEN Inc (NASDAQ: POZN) reported its Q4 EPS at $0.61, versus the consensus of $0.43. POZN reported its Q4 revenue at $29 million, versus the consensus of $25.8 million. POZN shares surged 5.74% to close at $5.16 yesterday. Read more from Benzinga's Company news.
-
Why I'm Buying Boring Stocks
Wednesday, March 9, 2011 - 1:55am | 2100I remember the good ol' days of the Internet Bubble in late 1999, early 2000. I bought Qualcomm (QCOM) at around $300 a share and watched it skyrocket to $800 a share in less than a year. Valuations didn't matter, only the stories behind the stocks. I had lofty ambitions of early retirement and...
-
Fast Money Picks For March 9th (IIF, RF, THC, ABT)
Tuesday, March 8, 2011 - 8:09pm | 202CNBC Fast Money's Tim Seymour is bullish on India. He wants to buy Morgan Stanley India Investment Fund Inc (NYSE: IIF) on Wednesday. Morgan Stanley India Investment Fund Inc (IIF) gained 1.56% in the regular trading session, and it added 1.45% in the after hours. Guy Adami likes Regions...
-
Pullback in Commodities Takes Pressure Off 03-08-2011
Tuesday, March 8, 2011 - 7:21pm | 902Cusick's Corner Of the three major indices, the S&Ps finished the strongest, well off the 50-Day Moving Average. The NASDAQ was a different story, finishing well in the green but straddling that 50-Day Moving Average. The Semis (SMH) were not helping the cause, but weakness in this sector will...
-
Options Brief: XenoPort, Inc. (XNPT)
Tuesday, March 8, 2011 - 1:02pm | 92Shares of XenoPort, Inc. (NASDAQ: XNPT) are higher on the session by 1.62%, trading at $7.55. Overall put volume is now running at 2.35x the daily average, with 63% of all puts traded being purchases on the offer. 2,555 contracts have traded on the session so far. XenoPort, Inc. is a...
-
Citi Comments On LLY 10-K
Tuesday, March 8, 2011 - 10:37am | 177After reviewing Eli Lilly's (NYSE: LLY) 10-K, Citi is providing some comments on the stock. “LLY's net debt position was -$200M leaving 2010 vs. -$2.2B/-$4.5B in ‘09/'08,” Citi writes. “LLY has $6.7B in cash/equivalents. We expect bus. dev. to be the priority for cash rather than debt pay down/...
-
Catalyst Pharmaceutical Partners, Inc. Announces Public Offering of 2.26M Shares at $1.12 per Share
Tuesday, March 8, 2011 - 10:10am | 115Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it has agreed to sell 2,259,943 shares of its common stock at a price of $1.12 per share, the closing price on March 7, 2011, in a firm commitment underwritten public offering. Catalyst expects to receive net proceeds, after...
-
Forest Laboratories Commences Tender Offer for Shares and Certain Notes and Warrants of Clinical Data, Inc.
Tuesday, March 8, 2011 - 9:34am | 184Forest Laboratories, Inc. (NYSE: FRX) today announced the commencement of a tender offer by its indirect wholly-owned subsidiary, Magnolia Acquisition Corp., for all outstanding shares of common stock, $0.01 par value, of Clinical Data, Inc. (NASDAQ: CLDA) for $30.00 per share in cash plus...
-
FDA Accepts New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes
Tuesday, March 8, 2011 - 9:03am | 114Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for dapagliflozin, an investigational compound for the treatment of adults with type 2 diabetes mellitus. A...
-
Jazz Pharmaceuticals Reports EPS of $0.63 vs. $0.60; Revenues $53.4M vs. $51.05M
Monday, March 7, 2011 - 5:03pm | 186Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the fourth quarter and full year ended December 31, 2010. Total revenues for the fourth quarter of 2010 were $53.4 million, compared to $38.3 million for the fourth quarter of 2009. Full year 2010 revenues were $173....
-
Merck Announces New Data Analyses for VICTRELIS Will Be Presented at The International Liver Congress
Monday, March 7, 2011 - 11:45am | 94Merck (NYSE: MRK) announced today that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver (EASL) annual meeting. The...
-
Calls Purchased on Mylan Inc. (MYL)
Monday, March 7, 2011 - 11:41am | 134Shares of Mylan Inc. (NYSE: MYL) are lower on the session by 0.32%, currently trading at $22.67. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying calls on the name today. A short...
-
Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility
Monday, March 7, 2011 - 9:01am | 123Bristol-Myers Squibb Company (NYSE: BMY) and WuXi PharmaTech (NYSE: WX) today announced that they have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications. Under the agreement, WuXi will build, equip and...
-
Merger Arbitrage Mondays – March 07, 2011
Monday, March 7, 2011 - 4:32am | 4874Merger activity decreased last week with four new deals announced and three deals closing. You can find all the deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: Total Number of Deals Closed in 2011 31 Total Number of Deals...
-
P&G, Colgate May Bid For Unilever's Sanex Unit
Sunday, March 6, 2011 - 12:06am | 239Unilever (NYSE: UN), the Anglo-Dutch consumer products giant, is shopping its Sanex unit, a business that was the company's primary reason for acquiring Sara Lee's (NYSE: SLE) international toiletries business in December for $1.69 billion, in sale that is being forced by the European Union due to...